Moderna, Inc. vs Vertiv Holdings Co — how do they compare? Moderna, Inc. trades at $213.13 (market cap $78.65B), while Vertiv Holdings Co trades at $244.92 (market cap $93.83B). The key difference: Vertiv Holdings Co is the larger of the two by market cap, and Vertiv Holdings Co pays a 0.1% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vertiv Holdings Co for 39 Days on average.
| MRNA | VRT | |
|---|---|---|
Market Cap | $78.65B | $93.83B |
Volume | 37,373,437 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $203.46 | $376.23 |
52-Week Low | $22.36 | $149.83 |
Typical Hold Time | 59 Days | 39 Days |
Enterprise Value | $74.80B | $94.06B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Vertiv Holdings (VRT) trades at $244.94, down 0.63% for the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company demonstrates strong fundamental performance with Q2 2026 EPS of $1.52 beating estimates of $1.42, continuing a pattern of earnings surprises. Revenue growth remains robust at $11.5B projected for 2026, while profitability metrics show improvement with net income margin expanding to 15.09%. Recent news highlights VRT's strategic positioning in AI data center infrastructure, though legal investigations following a stock drop present near-term concerns.
The investment outlook remains positive based on strong analyst consensus with 95% buy ratings and a $364.94 price target representing 49% upside potential. Key opportunities include VRT's leadership in data center cooling solutions amid AI infrastructure growth, while risks involve potential securities law violations investigation and competitive pressures in the industrial technology sector. The company's cash flow generation remains healthy with $1.2B net cash flow projected for 2026, supporting continued business expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →